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The Human immunodeficiency virus 1 derived capsid assembly inhibitor peptide (HIV-1 CAI-peptide) is a 
promising lead candidate for anti-HIV drug development. Its drawback, however, is that it cannot permeate cells 
directly. Here we report the transport of the pharmacologically active CAI-peptide into human lymphocytes and 
Human Embryonic Lung cells (HEL) using the BioShuttle platform. Generally, the transfer of pharmacologically 
active substances across membranes, demonstrated by confocal laser scanning microscopy (CLSM), could lead to 
a loss of function by changing the molecule’s structure. Molecular dynamics (MD) simulations and circular di-
chroism (CD) studies suggest that the CAI-peptide has an intrinsic capacity to form a helical structure, which 
seems to be critical for the pharmacological effect as revealed by intensive docking calculations and comparison 
with control peptides. This coupling of the CAI-peptide to a BioShuttle-molecule additionally improved its 
solubility. Under the conditions described, the HIV-1 CAI peptide was transported into living cells and could be 
localized in the vicinity of the mitochondria. 
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Introduction 
In the 2007 report of the global AIDS epidemic it 
was calculated that 30.6 million–36.1 million people 
world-wide were living with the human immunodefi-
ciency virus (HIV) at the end of 2007. An estimated 
1.8–4.1 million became newly infected with HIV and 
about 1.9–2.4 million people lost their lives by acquired 
immunodeficiency syndrome (AIDS). In several coun-
tries favourable trends in the incidence of AIDS or HIV 
are related to changes in individual behaviour. Pre-
vention programs raised a slight hope to reduce inci-
dence; however, the epidemics in the world’s most 
affected regions are highly diverse and, especially in 
Southern Africa and Eastern Europe, still expanding 
[1]. In addition to the national HIV prevention pro-
grams which should promote infection control prac-
tices in health-care settings, the development of effec-
tive curative therapeutic approaches for HIV-infected 
patients remains a considerable challenge for both the 
World Health Organization (WHO) and drug research. 
Current successful therapies involve the combination 
of the inhibition of the viral enzyme reverse tran-
scriptase, protease inhibitors and inhibitors of viral 
entry, described as highly active anti-retroviral ther-
apy (HAART) [2-4]. The striking success of HAART 
raised hope for the affected people. However, mean-
while, the number of drug-resistant variants of HIV 
increased and the exploration of new alternative tar-
gets is necessary for the next generation of antiviral 
drug development [5].  
The identification of active peptides as attractive 
candidates for intervention at the virus assembly level 
is one promising strategy. Briefly, the gag gene pro-
duces a 55-kilodalton kD Gag precursor protein (p55 
or Pr55Gag), which is expressed from the unspliced Int. J. Med. Sci. 2008, 5 
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viral mRNA [6]. During translation the N-terminus of 
p55 is myristoylated triggering its association to the 
cytoplasmic side of cell membranes [7] and the release 
of the budding of viral particles from the surface of 
infected cells. After budding, the virus aspartyl prote-
ase PR [8] cleaves p55, thus generating a set of smaller 
proteins and spacer peptides (SP) encoded by the viral 
pol gene during the process of viral maturation. The 
proteins are termed: matrix p17 (MA), nucleocapsid p9 
(NC), p4 and capsid p24 (CA) and SP1 and SP2 re-
spectively [9]. The assembly of Gag proteins into im-
mature viral particles followed by proteolytic disas-
sembly of the Gag shell to mature capsids are pivotal 
steps for the formation of infective HIV-1 [10]. The 
function of CA is of central importance in assembling 
the conical core of viral particles and so its inhibition is 
a desirable therapeutic target. Attempts have been 
made to develop capsid assembly inhibitors (CAI) 
based on Gag-derived peptide fragments, which are 
targeted to HIV Gag intermediates. Their intracellular 
biochemical processes and their mechanism of action 
in the intervention of the viral life cycle are not yet 
completely characterized. Molecules like the CAP-1 
[11, 12] also termed PA-457 [11, 13, 14] and most nota-
bly, the peptide-based CAI(Pep1) [15] are suitable lead 
compounds for anti HIV drug development. However, 
these show an insufficient bioavailability due to their 
limited water solubility. This situation demands in-
tensive efforts for development and characterization of 
delivery systems capable of transporting sufficient 
amounts of pharmacologically active agents such as 
CAI-peptides into the HIV-1 infected cells. In cell-free 
systems the antiviral activity of CAI-peptides has been 
documented and the discovery of peptide-based anti-
viral components is encouraging [15-17]. In this study 
we describe the synthesis and investigation of the 
modified peptide-based CAI-BioShuttle delivery plat-
form. 
Results and Discussion 
It is well documented that the transport efficiency 
of active substances can depend on the phys-
ico-chemical properties of the cargo [18]. In our study 
we characterized the transmembrane transport and the 
intracellular fate of the pharmacologically active 
CAI-probe by confocal laser scanning microscopy 
(CLSM) in comparison with the respective controls. 
Constructs harboring the protein transduction domain 
of HIV-1 Tat(48-60) as a transmembrane transport pep-
tide coupled via an enzymatic cleavable disul-
fide-bridge to a functional CAI-Inhibitor result in a 
HIV-1 Tat(48-60)-Cys-S-S-Cys-CAI-conjugate as shown 
in figure 1. Coupling of such therapeutic CAI-peptides 
to the modular BioShuttle [19] carrier, could provide 
effective reduction of viral loads of HIV. In this context 
the structural modalities of the CAI-peptides such as 
folding, which are essential for binding at the target 
site and for the pharmacological effect, remain to be 
elucidated. Further, their structural behavior after pas-
sage across the cellular membranes during their de-
livery and the structural requirements of their corre-
sponding target sites are still largely unexplored. With 
in silico methods and CD measurements we could 
predict the molecular structures of the cargos after 
passage through membranes and understand better 
their pharmacological behaviour.  
For delivery of the HIV-1 CAI into human cells a 
bi-modular peptide was developed and constructed 
consisting of a transport unit for transmembrane 
transport connected to a peptide with a capsid assem-
bly inhibitory (CAI) effect as a functional unit.  
To demonstrate the transport efficiency and to 
facilitate investigation of both the biochemical and the 
physico-chemical effects of the CAI, corresponding 
control peptides were also synthesized. An overview is 
shown in figure 1;c-f.  
Subcellular localization of the CAI-peptides by 
CLSM 
With confocal laser scanning microscopy we 
could demonstrate the intracellular distribution of the 
BioShuttle-delivered CAI-peptide (figure 1;c). Parallel 
to a scrambled control sample [CAICTRL-BioShuttle 
(figure 1;d)], the corresponding CAI-molecules with 
reverse peptide sequences [REVCAI-BioShuttle (figure 
1;e) and REVCAICTRL-BioShuttle (figure 1;f)] were in-
vestigated. 
We detected all investigated peptides, namely the 
CAI-peptide, its control and its corresponding reverse 
version in the cytoplasm and in nuclei of both periph-
eral T lymphocytes (PTL) cells and the human em-
bryonic lung (HEL).   
In human lymphocytes, as shown as a DIC pic-
ture in figure 2d, we demonstrated by CLSM, strong 
green fluorescence signals close to cell membrane and 
distributed in the cytoplasm (figure 2b). Red fluores-
cence signals (resulting from MitoTracker Red stain-
ing) were observed in compartments distributed in the 
cytoplasm but not in the cell nuclei (figure 2a). The 
overlay of the figures 2a, 2b, and 2d is shown in 2c and 
exhibits a distribution of fluorescence signals as fol-
lows: a part of the lymphocytes indicates a green 
fluorescence in the cell membrane range and a mixed 
fluorescence in the cytoplasm. Merging the two fluo-
rescence signals (green + red) results in a co-localizing 
orange fluorescence. This suggests a localization of the 
CAI-molecule in close vicinity to the mitochondria.  Int. J. Med. Sci. 2008, 5 
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Figure 1.  Schematized modular compositions of the CAI-BioShuttle and mass spectra of the investigated conjugates. Top 
part of the figure: The inhibitor peptide, control peptides, and the transmembrane transport module are connected with a sulfur bridge 
between the two cysteines (Single letter symbol C [bold]). Horizontally: c represents the modules of the CAI-BioShuttle, d the 
CAICTRL-BioShuttle, and e and f the BioShuttle connected to the reverse form of the CAI-inhibitor and the control, respectively. 
Vertically: c CAI-Inhibitor, d scrambled control and their corresponding peptides in reverse orientation (e and f), respectively. 
Middle column shows the transmembrane transport module. The link to the RCSB PDB Protein Data Bank is indicated. (
4);5)). The 
corresponding mass spectra of the above listed conjugates are shown at the lower part of the figure. 
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Figure 2.  Confocal investigations of treated and untreated human peripheral lymphocytes. The green fluorescence signals 
(2b) originate from both the biotinylated-CAI-BioShuttle and intrinsic biotin after treatment with Streptavidin, Alexa Fluor® 
488-solution. A strong red fluorescence signal of the mitochondrial staining by the used MitoTracker red is detectable. The overlay 
of the figures 2a and 2b as well as the corresponding DIC picture (2d) shows that the green fluorescence signal of the 
CAI-BioShuttle is co-localized with the red fluorescence of the mitochondrial compartment resulting in orange (mix fluorescence 
(2c). The bars indicate 20 µm. 
At present, the reason for the mitochondrial colo-
calization is unknown. In order to support these re-
sults and to exclude a possible colocalization to ly-
sosomes we also investigated the BioShut-
tle-CAI-peptide (figure 3) in HEL cells.  
Figure 3a shows a strong green fluorescence sig-
nal derived from the CAI-peptide appearing to be ly-
sosomally located, whereas the corresponding control 
(figure 3b) shows a very low diffuse signal originating 
from intrinsic biotin after treatment with Streptavidin, 
Alexa Fluor® 488-solution. The localization of active 
substances in lysosomes could alter the pharmacol-
ogical property, which could lead to a loss of function 
by degradation with intra-lysosomal enzymes. To ex-
clude this possibility, we used here the LysoTracker 
red staining. However figure 3a shows no significantly 
merged fluorescence signals, but instead distinct red 
lysosomes spatially separated from green fluorescence 
signals of the CAI-peptide in cytoplasm, mitochondria, 
and nuclei.  
 
 
Figure 3.  Confocal comparison of treated and untreated HEL cells. The green fluorescence signals originate from the bioti-
nylated-CAI-BioShuttle treated cells (3a) after staining with Streptavidin, Alexa Fluor® 488-solution. The cells harbour an addi-
tional red fluorescence signal after lysosome-staining by LysoTracker red. The untreated HEL cells (3b) show the intrinsic biotin as 
low green fluorescence background. The bars indicate 20 µm. 
Conformational preferences of CAI-inhibitor and 
CAI-BioShuttle 
In living cells the cytosolic reductive conditions 
are causing a cleavage of the coupling disulfide bridge 
of the CAI-BioShuttle and therefore the phys-
ico-chemical behavior of the free CAI-peptide is of 
particular interest. In order to gain some deeper in-
sight into the conformational preferences of the free 
CAI-Inhibitor in solution we performed ultraviolet 
circular dichroism (CD) measurements to estimate 
important characteristics of its secondary structure. 
For comparison the secondary structure of both con-Int. J. Med. Sci. 2008, 5 
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trols the REVCAI-Peptide (e) and the CAICTRL-Peptide 
(d) were determined also.  
None of these peptides was soluble in distilled 
water at a concentration of 100µg/ml. The investigated 
peptides showed unequal solubility: whereas the con-
trol peptides could be dissolved as a 1 mg/ml stock 
solution in 10% TFE: 90% distilled water; the 
CAI-peptide (c) could only be dissolved in 100% TFE 
at 1 mg/ml; all probes were subsequently diluted to 
100 µg/ml in 10% TFE. This water insoluble 
CAI-peptide was used for the CD measurements and 
revealed a strong β-sheet component (figure 4).  
 
Figure  4.  Polarity titration of the CAI-peptide. We per-
formed a titration to measure the influence of TFE on the 
structure as described in methods. The relative amount of sec-
ondary structure motifs of the CAI-Inhibitor is monitored here 
by UV-CD polarity titration. The ordinate reveals the relative 
percentage of structure type. The abscissa shows the concentra-
tion of TFE in water. 
To determine to what extent the peptides were 
capable of adopting the expected α-helical conforma-
tion when environmental conditions were altered, as 
for example when fitting to a binding site, the peptides 
were titrated in trifluoroethanol (TFE): H2O mixtures 
and CD spectra were measured to monitor any 
changes in the relative structural content. TFE is an 
apolar solvent that is miscible with water and is 
known to stabilize intra-molecular hydrogen bonds in 
proteins and their fragments [20, 21]. 
At 10% TFE the CAI inhibitor (figure 4) shows 
about 50% regular β-strands, whereas the two control 
peptides contain high levels of coil and turn and a 
relatively low amount of regular secondary structure. 
The fact that the CAI peptide (figure 1;c) shows the 
poor solubility characteristics in water as described 
above strongly suggests that oligomeric aggregates are 
formed under these conditions, characteristic of 
β-structures in aqueous solution. The other three pep-
tides (figure 1;def) behaved quite differently under 
polarity titration. The CAI-peptide (figure 1;c) is the 
only one capable of forming significant amounts of 
α-helical conformation and it is induced to do this at 
relatively low concentration of TFE. The three control 
peptides never formed large stretches of α-helical 
conformation and are not very sensitive to slight drops 
in polarity.  
Coupling of the CAI-peptide to the BioShuttle 
transporter led to a much better solubility, the complex 
being soluble in pure water at 1 mg/ml. To investigate 
the influence of the BioShuttle-transporter-peptide 
coupled to the CAI on the conformational preferences 
of the CAI-peptide (figure 1;c) we performed UV CD 
measurements of the CAI-BioShuttle construct as well 
as on the inverse CAI-peptide (d) attached to the 
BioShuttle using the same experimental procedure 
described above.   
 
Figure  5.  Polarity titration of the CAI-BioShuttle. We 
performed a titration to measure the influence of TFE on the 
structure as described in methods. The relative amount of sec-
ondary structure motifs of the CAI-Inhibitor is monitored here 
by UV-CD polarity titration. The ordinate reveals the relative 
percentage of structure type. The abscissa shows the concentra-
tion of TFA in water. 
Figure 5 shows for the CAI-BioShuttle peptide 
conjugate that the amount of regular structure is con-
siderably reduced as compared to the free CAI-peptide 
(figure 1;c). More particularly, no β-strand is now 
present while there is a pronounced (~25%) α-helical 
component. The question arises whether this can be 
related to the CAI moiety only or whether the 
BioShuttle moiety can form a stable helix and therefore 
may contribute also to the α-helical component of the 
CD spectrum. An indication that the helical structure 
in the CAI-BioShuttle conjugate arises from the CAI is 
that the inverse CAI-peptide (figure 1;e) attached to 
the BioShuttle shows even less tendency to form Int. J. Med. Sci. 2008, 5 
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regular secondary structure than the inverse CAI 
alone, the amount of α-helical conformation increasing 
linearly from zero at 10% TFE to only about 15% at 100 
% TFE. The discovery that the free CAI peptide, al-
though having a relatively short sequence, shows a 
pronounced tendency to adopt α-helical conformation 
under certain conditions coincides with other findings. 
It has been shown experimentally that the CAI-peptide 
exhibits a pronounced α-helical conformation for all 12 
amino acids when binding to the HIV-1 capsid 
C-terminal domain (PDB ID: 2BUO). The bound con-
formation shows a high complementarity to the HIV 
surface.  
For the conformation of the BioShuttle trans-
porter molecule alone an amphiphilic helix has been 
proposed [22, 23]. However no such helix is present in 
the TAT protein 3D structure solved by NMR where 
the BioShuttle peptide is a part of the sequence [24]. 
Our CD measurements also suggest that the BioShuttle 
moiety does not form a stable α-helix in solution. 
 
 
Figure 6.  Molecular dynamic simulations. The figure shows a secondary structure analysis of a 10 ns MD simulation of 
CAI-BioShuttle. BioShuttle looses helical structure (shown in red) after about 2 ns simulation time and prefers a ‘turn’–like (blue) 
orientation of the backbone torsions for the rest of the simulation time (top). Statistics of the secondary structure motifs per residue 
(bottom) showing that the probability for α-helical structure is low for the BioShuttle whereas the α-helical properties of the CAI 
moiety are very high. 
In order to gain further support for these as-
sumptions MD simulations in explicit solvent were 
performed to gain deeper insight on the stability of 
secondary structure motifs of CAI-BioShuttle and CAI 
on the atomistic level. The starting structure of 
CAI-BioShuttle was built as an α-helix in order to 
check whether a helical structure for the BioShuttle 
moiety is stable in solution (see Material and Meth-
ods). For the free CAI peptide the helical conformation 
as present in the crystal structure was used as a start-
ing structure. After about 2 ns simulation time the 
α-helix of the BioShuttle moiety starts to degrade (fig-
ure 6) whereas the helix of the CAI moiety remains 
completely stable over the whole simulation period of 
10 ns (figure 7). The overall secondary structure statis-
tics for the whole trajectory is about 30% α-helix, 45% 
turn and 25% coil and is in good agreement with the 
CD measurements. Three MD simulations of the free 
CAI-peptide in water were performed and the initial 
α-helix was stable for 10 ns (whole simulation period), 
6 ns and 2 ns respectively (data not shown).  Int. J. Med. Sci. 2008, 5 
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Figure 7.   Structural snapshot of the CAI-BioShuttle. The 
selected snapshot at the end of the 10 ns MD simulation shows 
the CAI adopting a conformation very close to the active con-
formation in the complex with the HIV-1 capsid C-terminal 
domain (PDB ID: 2BUO). The initial α-helix of the BioShuttle 
moiety disappeared. 
As a conclusion the MD simulations showed that 
CAI is able to exist in a α-helix in solution over a sig-
nificant amount of time in contrast to the BioShuttle 
peptide for which the stability of the α-helix is signifi-
cantly reduced. This is in excellent agreement with the 
CD measurements. However a simulation period of 10 
ns is probably too short to draw definite conclusions 
on the conformational equilibrium. MD simulations 
covering a much longer (microsecond) time period are 
underway. 
In silico interaction studies  
A ‘flexible docking’ approach using AutoDock 
3.05 [25] was applied to analyze whether the binding 
mode of the CAI to the HIV-1 capsid C-terminal do-
main (C-CA) receptor, as found in the crystal structure, 
could be reproduced in silico and whether there are 
alternative CAI conformations that could bind with a 
similar binding affinity. In a first approach we per-
formed docking experiments where no 
pre-organization of the CAI-peptide was assumed, 
(so-called ‘flexible docking’ experiments where all tor-
sion-angles of the peptide – except the peptide bonds - 
are allowed to adopt all possible conformations). Un-
fortunately it turned out that following the flexible 
docking approach we were not able to find any con-
formation, which was bound in a similar conformation 
or was bound as tightly as the one reported in the 
X-ray structure. The number of docking experiments 
performed using a genetic search algorithm can be 
regarded as very high (see Material and Methods) and 
are clearly at the limit on what is technically feasible at 
the moment. The reason why the conformation of CAI 
as present in the X-ray structure could not be repro-
duced even in a extensive flexible docking experiment 
is clearly because the bound conformation is highly 
organized and has therefore, because of the many ro-
tatable bonds, a very low probability of being found in 
an unbiased search. Only when the conformation of 
the core peptide backbone was pre-organized as an 
α-helix, complexes very similar to the crystal structure 
could be obtained from (semi-flexible) docking ex-
periments. If was found that the binding energy of CAI 
was more favorable for the helical conformations than 
for the more hairpin-like conformations which were 
mainly adopted in ‘best poses’ of the unbiased search. 
Evaluation of the individual energy contributions 
to the binding free energy as derived from the Auto-
Dock scoring function revealed a very unfavorable 
torsional term for the binding process. Because of the 
many bonds which can freely rotate in the free peptide, 
the loss in entropy when freezing out the rotations 
upon binding to the protein surface can evidently not 
be compensated by the gain of enthalpy on binding, so 
that the scoring function of the docking program used 
indicated no or only weak binding.  
These findings suggest that the binding affinity 
would dramatically benefit if the free CAI-peptide 
would have an intrinsic tendency to form an α-helical 
conformation, so that in the conformational ensemble 
present in solution, a significant amount of molecules 
would be pre-organized for binding already. In such a 
way, the loss of entropy in freezing out the specific 
conformation required for binding would be minimal.  
Summary 
The transfer of CAI-peptides across biomem-
branes is very poor and needs transporter molecules 
which can separate the CAI-cargo after the trans-
membrane passage in order to exclude undesired side 
effects like sterical interactions with the CAI-peptide 
cargo at the target site. The coupling of peptides to a 
BioShuttle carrier increased the bioavailability inside 
the cell. Intensive docking studies did not reveal al-
ternative CAI conformations that are strongly inter-
acting and failed to reproduce the binding mode of the 
crystal structure when the backbone of the 
CAI-peptide was not pre-organized as an α-helix. The 
reason for this is the high number of rotatable bonds in 
the peptide and the high specificity of the CAI-receptor 
interaction that can only be satisfied when the peptide 
is properly folded. However a complex very similar to 
the crystal structure could be reproduced by docking Int. J. Med. Sci. 2008, 5 
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experiments when the CAI backbone was 
pre-organized as an α-helix. Therefore it can be as-
sumed that only one highly specific conformation for 
strong binding to C-CA exists. The CD measurements 
and MD simulations suggest that an intrinsic α-helical 
conformation of the isolated CAI-peptide may exist, 
and is obviously not significantly hampered by at-
taching the BioShuttle peptide to enable transport 
through the membrane. Such a preferred folding of the 
CAI inhibitor seems to be an important factor for high 
affinity binding, since the entropic penalty for forming 
the required conformation on binding to CA is con-
siderably reduced. CD measurements revealed that the 
reverse and scrambled peptide do not show such a 
pre-organization which can explain their inactivity. 
Further studies with CAI-BioShuttle transporter 
should be considered for additional or alternative 
antiretroviral interventions.   
Material and Methods 
Chemical Synthesis and Purification of the 
CAI-BioShuttle 
For solid phase synthesis of the modules of 
CAI-BioShuttle and the control probes (figure 1) we 
employed the Fmoc-strategy [26, 27] in a fully auto-
mated multiple synthesizer (Syro II, MultiSyntech). 
Peptide chain assembly was performed using in situ 
activation of amino acid building blocks by 
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU). The biotin was built-in 
on the ε-amino group of lysine.  
The intermediates and products were purified by 
preparative HPLC on an YMC-Pack ODS. 5µm 120A 
reverse phase column (20 × 150 mm) using an eluent of 
0,1% trifluoroacetic acid in water (A) and 80% ace-
tonitrile in water (B). The peptides were eluted with a 
successive linear gradient of 25% B to 80% B in 30 min 
at a flow rate of 10 ml/min. The fractions correspond-
ing to the purified proteins were lyophilized. The pu-
rified material was characterized with analytical HPLC 
and laser desorption mass spectrometry (purity >90%) 
Reflex II (Bruker). 
The four different 14-mer peptide-modules, 
shown in figure 1, were oxidized together with the 
transmembrane transport module in the range of 2 mg 
× ml-1 in a 20% DMSO water solution. The reaction was 
completed after 5 hours. The formation of the sulfur 
bridge was controlled with matrix assisted laser de-
sorption mass spectrometry Reflex II (Bruker). The 
mass spectra of the investigated 
CAI-BioShuttle-constructs are represented in figure 1. 
Cell culture 
We obtained the human peripheral lymphocytes 
(PTL) from Institute of Pathology, University of Hei-
delberg. PTL were isolated from 10 ml native venous 
blood from a healthy donor by a lymphocyte prepara-
tion with Lymphoprep™ gradient (AXIS-Shield PoC 
AS, Oslo Norway) under sterile conditions maintained 
in RPMI 1640 supplemented with G-CSF and human 
embryonic lung cells (HEL) (obtained from DKFZ 
Tumorbank) in RPMI 1640 Medium without phenol 
red complemented with 10 % fetal bovine serum (FBS), 
(Gibco BRL). The cell cultures were grown at 37°C and 
5 % CO2. 
Cell preparation for confocal laser scanning mi-
croscopy (CLSM) 
Lymphocytes 
For estimation of the intracellular localization of 
the CAI-BioShuttle, four cell culture flasks with lym-
phocytes and 2 ml RPMI/G-CSF medium were incu-
bated in parallel with the CAI-BioShuttle constructs 
(figure 1;c) 1 h in a 100 nM final concentration. After 
the cells were washed and resuspended in phenol red 
free RPMI medium, the cell suspensions in a volume of 
100 µl were added to the glass slides (Lab Tek® II; 
Chamber Slide™ System). Their glass surface was 
treated with the BD Cell-Tak™ Cell and Tissue Adhe-
sive (BD Biosciences) before immobilization of the 
suspension cells according to the instructions. The 
immobilized living lymphocytes were stained with 
Mito Tracker Red (Molecular Probes) for 1 hour and 
the cell containing slide sections were rinsed twofold 
gently with Hanks (Gibco) before and after the fixation 
procedure with 3.7 % paraformaldehyde (PFA) for 15 
minutes at room temperature. The cell membranes 
were slightly perturbed by treatment with Triton X-100 
solution (0.1 % in Hank’s) on ice for 2 minutes, fol-
lowed by twice washing the cells. Then 150 µl of 
Streptavidin, Alexa Fluor® 488-solution (1:100 in PBS) 
(Molecular Probes) were applied to cells over 45 min-
utes at room temperature. The unbound Strepta-
vidin-conjugate was removed with Hank’s solution, 
again rinsed twice with Hank’s and embedded in 
Vectashield®Mounting Medium (Vector Laborato-
ries). The intracellular distribution of the Bio-
tin-labeled- Streptavidin Alexa Fluor® 488 
CAI-BioShuttle constructs was verified using a Zeiss 
Laser confocal microscope (LSM 510 UV). The optical 
slice thickness was 700 nm. 
HEL cells  
Adherent HEL cells were grown as described 
above and fixed as shown for the lymphocytes. Int. J. Med. Sci. 2008, 5 
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The excitation line of an Argon laser was used to 
detect the fluorescence signal from the Bio-
tin-labeled/Streptavidin Alexa Fluor® 488-labeled 
CAI-BioShuttle-conjugate. The spatial organization of 
lysosomes was shown by use of the LysoTracker Red 
fluorescence with the Zeiss Filter Set 31 (578 nm exci-
tation and 599 nm emission). To increase the contrast 
of the optical sections, 12–20 single exposures were 
averaged. The image acquisition  parameters were 
adapted to show signal intensities in accordance with 
the visible microscopic image. The same experiments 
were  performed with scrambled random se-
quence-constructs and their reverse amino acid se-
quence as controls respectively (figure 1). 
Circular Dichroism Studies 
Far UV circular dichroism spectra were measured 
from 190-240 nm using a Jasco J-710 automatic re-
cording spectral polarimeter calibrated with 0.05% 
β-androsterone in dioxane. The scanning speed was 5.0 
nm/minute with a 4.0 s time constant. Spectra dis-
played result from four-fold signal averaging followed 
by Fast Fourier Transform to remove residual noise; 
similarly treated baselines were subtracted before 
converting from millidegrees to θmrw (mean residue 
ellipticity) for secondary structure analysis using the 
computer program PEPFIT [28]. Samples were meas-
ured in a 1.0 mm dichroically neutral quartz cuvette at 
a concentration of 100 µg/ml. TFE titration ran from 
0% to 100% TFE in 20% steps with distilled water as 
the aqueous component. 
Molecular Dynamics simulation 
3D coordinates of the HIV-1 capsid C-terminal 
domain (C-CA) in complex with CAI [16] were re-
trieved from the Protein Data Bank [29] (PDB ID: 
2BUO, resolution 1.7 Å). The coordinates of the CAI 
peptide were extracted and were used as starting 
conformation for MD simulations of the free peptide in 
water. The BioShuttle peptide (GRKKRRQRRRPPQC) 
and the elongated CAI sequence (ITFEDLLDYYGPKC) 
were built separately from AMBER building blocks 
using the LEAP module of the AMBER package [30]. 
Linking of the two chains by forming a disulfide bond 
between the C-terminal cysteines and folding of the 
molecule into the starting conformation was per-
formed using the Conformational Analysis Tools 
(CAT) [31] software applying the method briefly out-
lined here: for the CAI fragment the torsion angles 
were extracted from the crystal structure and imposed 
on the ITFEDLLDYYGP sequence, the rest of the chain 
was folded into an α-helix by setting the φ/ψ torsions to 
-57°/-47° respectively. The peptides were solvated in a 
box of SPC water and ions were added to counterbal-
ance the charge of the peptides. The particle-mesh 
Ewald approach was used to account for long-range 
electrostatic effects. Temperature and pressure was 
held constant at 300 K and 1 bar using Berendsen 
methods [32]. All MD simulations were performed for 
10 ns using the GROMACS package and the 
GROMOS96 forcefield [33]. Analysis of the stability of 
secondary structure motifs during the MD simulation 
has been performed using STRIDE [34] interfaced with 
CAT. Igor Pro (www.wavemetrics.com) has been used 
to generate the scientific plots. VMD [35] was used for 
molecular graphics.  
Flexible Docking 
AutoDock 3.05 was used to perform the docking 
experiments [25]. The various files required as input 
for AutoDock were created with the help of 'Auto-
DockTools' 
(http://www.scripps.edu/~sanner/python/adt/). 
The genetic algorithm with local search option 
(GA-LS) as implemented in AutoDock was used to 
dock the flexible peptide. For the ‘flexible’ docking 
experiments backbone (φ/ψ) and side chain torsions 
were allowed to rotate (in total 32 torsions which is the 
maximum number of flexible torsions that AutoDock 
can handle in the standard installation) whereas in the 
‘semi flexible’ docking experiments only the side chain 
torsions were allowed to rotate. The receptor was 
treaded as rigid for the docking experiments. For the 
‘flexible’ docking 333 AutoDock jobs were started on a 
HPC cluster (AMD Opteron 250 processor with 2.4 
MHz) each performing 256 GA-LS runs (106 energy 
evaluations each) giving rise to 85248 docked CAI 
structures. The overall CPU time was about 7000 
hours. The docking protocol with semi-flexible CAI 
implied 44 AutoDock jobs resulting in 11264 docked 
solutions. CAT was used to merge the output data of 
the AutoDock runs, to perform the analysis of the en-
tire dataset and organize the results in such a way, that 
complexes exhibiting a strong binding can be easily 
visualized using standard display programs.   
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